Kidney Neoplasms
Welcome,         Profile    Billing    Logout  
 125 Companies   180 Products   180 Products   118 Mechanisms of Action   5 Trials   1274 News 


12345678910111213...2526»
  • ||||||||||  Trial completion, Trial completion date, Checkpoint inhibition, Checkpoint block:  PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy (clinicaltrials.gov) -  Feb 8, 2019   
    P1,  N=20, Completed, 
    Active, not recruiting --> Completed | Trial completion date: May 2017 --> Feb 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2015 --> Dec 2018
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  Sequential Therapy in Metastatic Renal Cell Carinoma (clinicaltrials.gov) -  Feb 6, 2019   
    P2,  N=22, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2015 --> Dec 2018 Active, not recruiting --> Completed | N=100 --> 22 | Trial completion date: May 2016 --> Sep 2016 | Trial primary completion date: May 2016 --> Sep 2016
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Urine Proteome of Surgical Patients and Healthy Volunteers (clinicaltrials.gov) -  Jan 7, 2019   
    P=N/A,  N=664, Completed, 
    Active, not recruiting --> Completed | N=100 --> 22 | Trial completion date: May 2016 --> Sep 2016 | Trial primary completion date: May 2016 --> Sep 2016 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Jul 2016 | Trial primary completion date: Dec 2018 --> Jul 2016
  • ||||||||||  cisplatin / Generic mfg., gemcitabine / Generic mfg., sorafenib / Generic mfg.
    Trial completion, Trial completion date, Metastases:  Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma (clinicaltrials.gov) -  Nov 20, 2018   
    P2,  N=26, Completed, 
    Trial completion date: May 2016 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Jun 2018
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Trial completion, Enrollment change, Trial primary completion date:  Cardiovascular Effects of Sunitinib Therapy (CREST) (clinicaltrials.gov) -  Oct 2, 2018   
    P=N/A,  N=98, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=20 --> 98 | Trial primary completion date: Apr 2017 --> Dec 2017
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma (clinicaltrials.gov) -  Oct 2, 2018   
    P=N/A,  N=60, Completed, 
    Recruiting --> Completed | N=20 --> 98 | Trial primary completion date: Apr 2017 --> Dec 2017 Recruiting --> Completed | Trial completion date: Jan 2018 --> Jul 2018 | Trial primary completion date: Jan 2016 --> Jul 2018
  • ||||||||||  davamotecan pegadexamer (EP0057) / Ellipses Pharma, Avastin (bevacizumab) / Roche
    Trial completion, Trial primary completion date, Combination therapy, Metastases:  CRLX101 Plus Bevacizumab in Advanced RCC (clinicaltrials.gov) -  Aug 29, 2018   
    P1b,  N=22, Completed, 
    Trial primary completion date: Jul 2020 --> Apr 2016 Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Jul 2017
  • ||||||||||  Avastin (bevacizumab) / Roche, carotuximab IV (ENV-105) / Kairos Pharma
    Enrollment change, Combination therapy, Metastases:  Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov) -  Jul 3, 2018   
    P2,  N=59, Completed, 
    N=25 --> 10 | Completed --> Terminated; Pharmaceutical collaborator pulled funding. N=88 --> 59
  • ||||||||||  rocapuldencel-T (CMN-001) / CoImmune, SCM Lifescience
    Trial completion date, Trial termination, Trial primary completion date:  A Rollover Protocol for Subjects Previously Treated With AGS-003 (clinicaltrials.gov) -  Jun 27, 2018   
    P2,  N=2, Terminated, 
    N=88 --> 59 Trial completion date: Dec 2017 --> May 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2017 --> May 2018; Lack of efficacy
  • ||||||||||  rocapuldencel-T (CMN-001) / CoImmune, SCM Lifescience
    Trial termination, Trial primary completion date, Metastases:  ADAPT: Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) -  Jun 14, 2018   
    P3,  N=462, Terminated, 
    Trial completion date: Dec 2017 --> May 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2017 --> May 2018; Lack of efficacy Active, not recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Apr 2018; Lack of efficacy
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Vaccine Therapy in Treating Patients With Kidney Cancer (clinicaltrials.gov) -  Apr 25, 2018   
    P1,  N=15, Completed, 
    N=40 --> 18 Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Apr 2018 | Trial primary completion date: Nov 2019 --> Apr 2018
  • ||||||||||  famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    Trial termination, Metastases:  A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer (clinicaltrials.gov) -  Apr 18, 2018   
    P2,  N=150, Terminated, 
    Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Apr 2018 | Trial primary completion date: Nov 2019 --> Apr 2018 Active, not recruiting --> Terminated
  • ||||||||||  Votrient (pazopanib) / Novartis, BeiGene
    Trial completion:  Study To Assess Long Term Safety Of Pazopanib (clinicaltrials.gov) -  Apr 12, 2018   
    P1,  N=188, Completed, 
    Active, not recruiting --> Terminated Active, not recruiting --> Completed
  • ||||||||||  buparlisib (AN2025) / Novartis, Adlai Nortye
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies (clinicaltrials.gov) -  Mar 19, 2018   
    P1,  N=43, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: May 2018 --> May 2017 | Trial primary completion date: Mar 2018 --> May 2017
  • ||||||||||  sirolimus / Generic mfg.
    Trial completion date, Trial primary completion date, Metastases:  A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Mar 8, 2018   
    P1,  N=64, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: May 2018 --> May 2017 | Trial primary completion date: Mar 2018 --> May 2017 Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Nov 2016
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule (clinicaltrials.gov) -  Mar 6, 2018   
    P2,  N=117, Completed, 
    Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Nov 2016 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Sep 2017 | Trial primary completion date: Dec 2017 --> Sep 2017
  • ||||||||||  Trial completion date, Trial primary completion date:  Vaccine Therapy in Treating Patients With Kidney Cancer (clinicaltrials.gov) -  Feb 27, 2018   
    P1,  N=15, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Sep 2017 | Trial primary completion date: Dec 2017 --> Sep 2017 Trial primary completion date: Nov 2018 --> Nov 2019 | Trial completion date: Nov 2018 --> Nov 2019
  • ||||||||||  Trial completion, Trial completion date, Trial initiation date, Trial primary completion date:  Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes (clinicaltrials.gov) -  Feb 22, 2018   
    P3,  N=210, Completed, 
    Trial primary completion date: Nov 2018 --> Nov 2019 | Trial completion date: Nov 2018 --> Nov 2019 Active, not recruiting --> Completed | Trial completion date: May 2018 --> Feb 2018 | Initiation date: May 2012 --> May 2012 | Trial primary completion date: May 2018 --> Feb 2018
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Perfusion Scanning's for Kidney Tumors (clinicaltrials.gov) -  Jan 24, 2018   
    P=N/A,  N=56, Completed, 
    N=99 --> 15 Recruiting --> Completed | N=100 --> 56 | Trial primary completion date: Dec 2018 --> Jan 2018
  • ||||||||||  vatalanib (PTK787) / Novartis, Bayer
    Trial completion, Trial primary completion date, Combination therapy, Metastases:  Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Jan 17, 2018   
    P1,  N=96, Completed, 
    N=20 --> 14 | Active, not recruiting --> Terminated; The sponsor's clinical program for the agent used in this study was discontinued. Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009
  • ||||||||||  Tookad (padeliporfin) / ImPact Biotech
    Enrollment change:  Vascular Targeted Photodynamic Therapy T1a Renal Tumours (clinicaltrials.gov) -  Jan 10, 2018   
    P2a,  N=5, Terminated, 
    Active, not recruiting --> Completed N=12 --> 5
  • ||||||||||  Votrient (pazopanib) / Novartis, BeiGene
    Trial primary completion date:  Study To Assess Long Term Safety Of Pazopanib (clinicaltrials.gov) -  Jan 8, 2018   
    P1,  N=195, Active, not recruiting, 
    N=12 --> 5 Trial primary completion date: Dec 2017 --> Mar 2018